ProKidney Corp. (PROK) Stock Forecast
PROK analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 7 analysts
- Price target
- $6.25 average of analyst targets
- Upside to target
- +369.9% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.12
- 52-week range
- $1.33 – $3.30
PROK analyst ratings
7 analystsNumber of analysts at each rating.
PROK price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PROK earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.17 | −$0.12 | −$0.12 | −16.5% | 5 |
| Current fiscal year (2026) | −$0.56 | −$0.66 | −$0.50 | −$0.52 | −8.1% | 5 |
| Next fiscal year (2027) | −$0.59 | −$0.78 | −$0.42 | −$0.56 | −4.3% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PROK revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $124,600 | $0 | $200,000 | −42.6% | 5 |
| Current fiscal year (2026) | $507,140 | $0 | $800,000 | −43.2% | 7 |
| Next fiscal year (2027) | $494,200 | $0 | $800,000 | −2.5% | 5 |
PROK EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PROK revenue: reported and forecast
PROK EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.14 | −$0.14 | −$0.14 | −$0.14 | −9.1% | 1 up · 2 down |
| Current fiscal year (2026) | −$0.70 | −$0.54 | −$0.54 | −$0.54 | −$0.56 | −19.7% | 0 up · 5 down |
| Next fiscal year (2027) | −$0.73 | −$0.58 | −$0.58 | −$0.58 | −$0.59 | −19.6% | 1 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PROK earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PROK beat in 8 of 12.
What analysts expect from PROK
7 analysts cover ProKidney; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $6.25, 369.9% above the latest close of $1.33. Analysts expect earnings of −$0.56 per share for 2026, −8.1% from a year earlier. For 2027 the average estimate is −$0.59 per share on revenue of $0.5 million. ProKidney beat the EPS estimate in 8 of the last 12 quarters.
Related: PROK income statement, PROK key metrics, PROK chart. See the PROK stock overview for the latest quote and news.
PROK forecast FAQ
What is ProKidney's price target?
The average analyst price target for ProKidney is $6.25, 369.9% above the latest close of $1.33.
Is ProKidney a buy, hold or sell?
Of 7 analysts covering ProKidney, 4 rate it a strong buy, 0 a buy, 2 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is ProKidney's EPS forecast?
Analysts forecast −$0.56 per share for 2026 (range −$0.66 to −$0.50); for 2027 the estimate is −$0.59.
What is ProKidney's revenue forecast?
The average revenue estimate for 2026 is $0.5 million, growth of −43.2%; for 2027 it is $0.5 million.
When does ProKidney report earnings?
ProKidney is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.12.
Does ProKidney usually beat earnings estimates?
ProKidney reported EPS at or above the analyst estimate in 8 of the last 12 quarters.